Evidence map›Paper›PMID 23465500›Full record

ReviewSeminars in nephrology2013

A systems biology preview of the relationships between mineral and metabolic complications in chronic kidney disease.

L Darryl Quarles

Abstract readReview
In one paragraph

Review in Seminars in nephrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Circulating microRNAs and vascular calcification in hemodialysis patients.The Journal of international medical research · 2019
    Article
  6. Review
  7. Fibroblast Growth Factor 23 is Associated With Adiposity in Patients Receiving Hemodialysis: Possible Cross Talk Between Bone and Adipose Tissue.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2018
    Article
  8. Phosphate Toxicity in CKD: The Killer among Us.Clinical journal of the American Society of Nephrology : CJASN · 2016
    Review
  9. PTH and Vitamin D.Comprehensive Physiology · 2016
    Review
  10. Sclerostin and CKD-MBD.Current osteoporosis reports · 2015
    Review
  11. Vascular calcification and renal bone disorders.TheScientificWorldJournal · 2014
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

L Darryl QuarlesDepartment of Medicine and Division of Nephrology, University of Tennessee Health Science Center, Memphis, TN 38163, USA. dquarles@uthsc.edu
University of Tennessee Health Science Center · US

Funding

Regulation and Function of FGF23R01AR045955 · NIAMS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI QUARLES, L DARRYL · 1999 to 2016
$4.8M
NIAMS NIH HHS R01 AR045955
6 · The paper itself

Abstract

There are emerging data that the skeleton is connected to systemic biological functions through the release of two osteoblast-/osteocyte-derived hormones, fibroblastic growth factor 23 (FGF23) and undercarboxylated osteocalcin (Ocn). FGF23 is important in the regulation of phosphate and vitamin D metabolism, whereas Ocn participates in endocrine networks, coordinating bone and fat mass, energy metabolism, and sex hormone production. Bone remodeling and mineralization per se, along with the hormones leptin, insulin, glucocorticoids, PTH, and 1,25(OH)2D, regulate the release of FGF23 and Ocn, leading to complex cross-talk and coordination between endocrine networks previously thought to be distinct. These pathways are particularly important in chronic kidney disease, in which both FGF23 and Ocn are increased. Although these hormones initially serve an adaptive role, with progressive loss of renal function they show maladaptive effects, particularly on the cardiovascular system, through multiple mechanisms, including possible cross-talk with the renin angiotensin system. The complex interconnections between the various endocrine networks in chronic kidney disease may account for the difficulty in treating the uremic state.

Indexed as

AnimalsBone Diseases, MetabolicFibroblast Growth Factor-23Fibroblast Growth FactorsHumansOsteoblastsOsteocalcinOsteocytesParathyroid HormonePhosphatesRenal Insufficiency, ChronicRenin-Angiotensin SystemSystems BiologyVitamin DFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsOsteocalcinParathyroid HormonePhosphatesVitamin D

Identifiers

PMID23465500
PMCPMC5079533
OpenAlexW2111253096

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.